Ethinyl Estradiol; Norethindrone Acetate Patent Expiration
Ethinyl Estradiol; Norethindrone Acetate is Used for preventing pregnancy in women using oral contraceptives. It was first introduced by Parke Davis Laboratories Div Warner Lambert Co
Ethinyl Estradiol; Norethindrone Acetate Patents
Given below is the list of patents protecting Ethinyl Estradiol; Norethindrone Acetate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Femlyv | US12178824 | Orodispersible formulations | Jun 24, 2041 | Millicent Pr |
| Lo Loestrin Fe | US7704984 | Extended estrogen dosing contraceptive regimen | Feb 02, 2029 | Apil |
| Lo Minastrin Fe | US7704984 | Extended estrogen dosing contraceptive regimen | Feb 02, 2029 | Apil |
| Taytulla | US6652880 | Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants |
Mar 29, 2020
(Expired) | Apil |
| Lo Minastrin Fe | US6667050 | Chewable oral contraceptive |
Apr 06, 2019
(Expired) | Apil |
| Minastrin 24 Fe | US6667050 | Chewable oral contraceptive |
Apr 06, 2019
(Expired) | Apil |
| Loestrin 24 Fe | US5552394 | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
Jul 22, 2014
(Expired) | Teva Branded Pharm |
| Lo Loestrin Fe | US5552394 | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
Jul 22, 2014
(Expired) | Apil |
| Lo Minastrin Fe | US5552394 | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
Jul 22, 2014
(Expired) | Apil |
| Minastrin 24 Fe | US5552394 | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
Jul 22, 2014
(Expired) | Apil |
| Taytulla | US5552394 | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
Jul 22, 2014
(Expired) | Apil |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Ethinyl Estradiol; Norethindrone Acetate's patents.
Latest Legal Activities on Ethinyl Estradiol; Norethindrone Acetate's Patents
Given below is the list recent legal activities going on the following patents of Ethinyl Estradiol; Norethindrone Acetate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| File Marked Found | 05 Apr, 2017 | US6652880 |
| Recordation of Patent Grant Mailed Critical
| 25 Nov, 2003 | US6652880 |
| Patent Issue Date Used in PTA Calculation Critical
| 25 Nov, 2003 | US6652880 |
| Issue Notification Mailed Critical
| 06 Nov, 2003 | US6652880 |
| Receipt into Pubs | 16 Oct, 2003 | US6652880 |
| Application Is Considered Ready for Issue Critical
| 13 Oct, 2003 | US6652880 |
| Receipt into Pubs | 01 Oct, 2003 | US6652880 |
| Issue Fee Payment Received Critical
| 25 Aug, 2003 | US6652880 |
| Issue Fee Payment Verified Critical
| 25 Aug, 2003 | US6652880 |
| Receipt into Pubs | 18 Aug, 2003 | US6652880 |
Ethinyl Estradiol; Norethindrone Acetate's Family Patents
